�������

The successful and safe delivery of therapeutics relies on understanding how easily drugs can pass through biological barriers which protect cells. 

Drug permeability testing is essential in determining whether medicines can reach their intended targets in the body, but scientists have long struggled to achieve accurate and reproducible data. 

There are three ways to measure the success of drug delivery; in the lab, in animals and humans, and using advanced computer simulations. However, the difficult process of matching the results from these three areas of testing continues to be a problem.

Bridging the gap

- led by the ������� in collaboration with the University of Southampton, King’s College London, and the Massachusetts Institute of Technology - has developed a set of general guidelines for how to compare the values from lab experiments, molecular simulations and AI.

Dr Christian Jorgensen from the �������’s School of Medicine, Pharmacy and Biomedical Sciences, said: “Drug permeability testing is very important because if a drug can’t cross the right barriers, it won’t work properly, no matter how good it looks on paper. 

“I spent some years working at a hospital in the US trying to compare permeability data measured in people and animals with computer simulated data, which was no easy feat. Each method of testing has an advantage, so ultimately this is about ensuring the best quality drugs and therapeutics make it to market.

“When you seek drug approval, the more evidence you can supply on the effectiveness of it, the more likely it will be approved. That’s why we’re seeing more and more convergence of the three testing areas.”

Only 14 percent of drugs entering clinical trials between 2000 and 2015 received FDA approval in the US. Enhanced permeability testing could improve success rates by ensuring drugs effectively reach their targets while minimising side effects.

Testing the most complex systems

The study, , highlights the importance of understanding how drugs move across all biological barriers. This includes the most complex systems like the blood-brain barrier, which is a significant obstacle in delivering treatments for neurological conditions.

Dr Jorgensen explained: “The strength of the paper is we’ve not just tested the guidelines against a simple system of barriers in the body - we used one of the most complicated, which is also highly relevant in health and therapeutics.

“This work has the potential to accelerate the development of life-saving drugs, especially for conditions like brain disorders where drug delivery is notoriously difficult."

The new guidelines provide a comprehensive roadmap for improving the testing and modeling of drug permeability by looking at the differences of three areas:

• On computers (In Silico): Scientists use computer programmes to predict how a drug might move through the body based on its chemical properties.

• In the lab (In Vitro): They test the drug on cells in dishes to see how it behaves in controlled environments.

• In humans/animals (In Vivo): Sometimes, they test the drug in a living body to see how it works.

Consistency and collaboration

The toolkit emphasises critical factors such as ensuring experimental consistency, addressing data variability, and adopting FAIR (Findable, Accessible, Interoperable, Reusable) principles for data sharing. 

The authors also stress the importance of collaboration across fields to improve the accuracy of permeability testing and uncover new insights into drug delivery mechanisms.

said: “By providing clear benchmarks and recommendations, we hope to unify and refine permeability testing practices, and provide  a standardised set of guidelines. 

"This is not just about improving individual experiments, it’s about creating a framework that allows the scientific community to compare their discoveries reliably." 

The study was funded by the and supported by a fellowship from the .